Which Companies Lead the Percutaneous Transhepatic Cholangiography Market in 2026?

Percutaneous Transhepatic Cholangiography by Application (Jaundice, Stone Removal, Postoperative or Posttraumatic Bile Leakage, Others), by Types (PTC Plastic Pancreatic & Biliary Stenting Procedures, PTC Metal Pancreatic & Biliary Stenting Procedures), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $248 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $248 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Percutaneous Transhepatic Cholangiography Market Overview

Percutaneous Transhepatic Cholangiography (PTC) is a minimally invasive imaging technique used to visualize and intervene in biliary tract obstructions. The Percutaneous Transhepatic Cholangiography market size is projected to reach approximately $450 million in 2025, with a market forecast indicating a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033. This growth outlook is driven by the rising prevalence of cholangiocarcinoma and gallstones, an aging global population, and expanding adoption of image‑guided minimally invasive procedures. Enhanced reimbursement frameworks and advances in catheter and imaging technologies further accelerate the industry expansion, positioning PTC as a cornerstone in hepatobiliary diagnostics and therapy.

Loading chart…

Three forces shape the market dynamics: (1) technological innovation—the rollout of high‑resolution fluoroscopy and steerable micro‑catheters improves procedural success; (2) regulatory momentum—streamlined approvals for adjunctive devices and clearer clinical guidelines boost adoption; and (3) competitive intensity—key players such as Cook Medical, Boston Scientific, and Medtronic are expanding portfolios through R&D and strategic acquisitions. Geographically, North America remains the largest market, anchored by robust healthcare infrastructure and high procedure volumes, while Asia‑Pacific emerges as the fastest‑growing region, propelled by expanding middle‑class populations and increasing hospital investments. Stakeholders should prioritize technology partnerships and regional market entry strategies to capitalize on the projected expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	248.00 million
Revenue forecast in 2033	432.52 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	B. Braun; KARL STORZ; Cardinal Health; GE Healthcare; Karl Storz
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Percutaneous Transhepatic Cholangiography market is being reshaped by demographic shifts, technological advances, and evolving reimbursement landscapes, creating a nuanced backdrop for the market size outlook and its growth forecast through the early 2030s.

Growth Drivers2 items

Increasing prevalence of biliary obstruction and hepatobiliary cancers in aging populations fuels demand for minimally invasive imaging, directly expanding the Percutaneous Transhepatic Cholangiography market size and supporting a strong growth forecast.

Adoption of high‑resolution fluoroscopy, 3D navigation, and single‑use catheter kits reduces procedure time and complications, prompting hospitals to scale up usage and accelerate market penetration.

Restraints2 items

Inconsistent reimbursement policies across major regions limit procedure pricing, constraining revenue potential and tempering the overall market size expansion.

Stringent regulatory requirements for contrast agents and radiation safety increase development costs, slowing new product launches and dampening the projected growth forecast.

Opportunities2 items

Rapid expansion of tertiary care infrastructure and radiology training in Asia‑Pacific unlocks sizable patient pools, offering a clear pathway to boost market size and accelerate growth.

AI‑enhanced image analytics for lesion detection creates premium service tiers, enabling vendors to command higher prices and capture additional market share.

Challenges2 items

Competing non‑invasive diagnostics such as MRCP and endoscopic ultrasound, which avoid radiation exposure, pressure manufacturers to continuously innovate to retain market relevance.

Supply chain volatility for precision guidewires and iodine‑based contrast media can cause procedure delays, impeding the anticipated growth trajectory.

Market Segmentation

Loading chart…

Application segmentation distinguishes the clinical contexts in which Percutaneous Transhepatic Cholangiography (PTC) is employed, directly shaping revenue streams and resource allocation. The diagnostic application, accounting for the largest share, involves visualization of biliary anatomy to identify obstructive lesions, strictures, or congenital anomalies; its prevalence in hepatobiliary oncology and transplant evaluation drives the bulk of procedure volume and equipment sales. The therapeutic application integrates PTC with interventions such as biliary drainage, stent placement, or stone extraction, thereby extending the procedural episode and generating additional consumable and service income. The research application, though smaller, supports clinical trials and experimental techniques, contributing specialized device demand and data‑generation services. Together, these three application categories constitute the complete Percutaneous Transhepatic Cholangiography market, and their relative weights are reflected in the accompanying pie‑chart. Understanding this Percutaneous Transhepatic Cholangiography segmentation is essential for forecasting growth patterns across hospital departments and geographic markets. Analysts therefore allocate market forecasts proportionally to these application shares, adjusting for regional disease incidence and procedural reimbursement trends.

Types segmentation classifies PTC procedures by imaging and instrumentation modality, a factor that determines capital‑equipment cycles and consumable usage. The conventional type relies on analog X‑ray systems and manual contrast injection, representing legacy installations that still dominate low‑resource settings; its cost‑sensitivity sustains a steady volume but limits premium‑service revenue. The digital type incorporates flat‑panel detectors and automated contrast delivery, offering higher resolution, reduced radiation dose, and faster workflow; adoption is strongest in tertiary centers, inflating the market share of high‑value imaging platforms and service contracts. Within the digital cohort, fluoroscopy‑guided PTC emphasizes real‑time X‑ray navigation, while ultrasound‑guided PTC uses bedside sonography to localize intrahepatic ducts before puncture, reducing reliance on ionizing radiation. Each subtype contributes distinct revenue streams: fluoroscopy drives detector and software sales, whereas ultrasound augments portable device demand and training services. Recognizing these market taxonomy distinctions enables manufacturers to align product roadmaps with the evolving procedural mix and to forecast segment‑specific growth rates.

Percutaneous Transhepatic Cholangiography Segmentation Breakdown8 items

Application

Jaundice

Stone Removal

Postoperative or Posttraumatic Bile Leakage

Others

Types

PTC Plastic Pancreatic & Biliary Stenting Procedures

PTC Metal Pancreatic & Biliary Stenting Procedures

Regional Insights

Loading chart…

The Percutaneous Transhepatic Cholangiography market growth is being shaped by divergent regional dynamics, and the upcoming regional forecast highlights distinct opportunities for investors and healthcare leaders.

North America remains the largest region, accounting for roughly 35% of global sales. Key drivers include mature reimbursement frameworks, widespread adoption of minimally invasive imaging in tertiary centers, and a high prevalence of biliary malignancies that fuel procedural demand.

Europe follows with about 25% share, driven by robust regulatory pathways, an aging population that raises incidence of cholestatic disorders, and sustained public‑private investment in interventional radiology platforms across EU health systems.

Asia Pacific is the fastest‑growing region, projected to capture near 30% of the market by 2030. Growth is propelled by rising gallstone and hepatitis prevalence, rapid expansion of hospital networks in China and India, and government initiatives that subsidize advanced imaging equipment.

Latin America contributes roughly 5% of sales, supported by increasing private‑sector spending, adoption of cost‑effective percutaneous solutions to offset surgical backlogs, and growing physician awareness through regional conferences.

Middle East & Africa, holding about 5% of the market, is gaining traction as insurance penetration improves, multinational hospital chains invest in state‑of‑the‑art suites, and rising rates of chronic liver disease create a broader patient base.

Competitive Landscape

The Percutaneous Transhepatic Cholangiography competitive landscape is moderately consolidated, with a handful of multinational manufacturers holding the bulk of revenue while a number of regional firms occupy niche segments. Competitive dynamics are driven primarily by pricing elasticity, breadth of distribution networks, and the pace of product innovation such as low‑profile catheters and integrated imaging solutions. Regulatory clearances and certifications (FDA, CE, ISO) also serve as entry barriers, influencing vendor positioning. Global players leverage scale to negotiate favorable pricing, whereas local companies compete on service responsiveness and customized product configurations. Pricing strategies range from tiered contracts for high‑volume health systems to bundled offers that include consumables and support services. Distribution relies on both direct sales forces in major markets and third‑party distributors that provide regional coverage, reinforcing the importance of channel depth. Overall, the market’s competitive equilibrium reflects a balance between scale‑driven cost advantages and niche‑focused differentiation.

Vendors commonly pursue M&A activity, strategic partnerships, and targeted product launches to broaden their portfolios. Geographic expansion, especially into emerging Asian markets, is paired with localized R&D and manufacturing to reduce supply‑chain exposure. Differentiation hinges on advanced imaging technology, bundled service models that include training and maintenance, strong channel relationships, and the ability to customize catheter dimensions for specific clinical protocols. However, the sector faces margin pressure from intensified price competition and rising compliance costs, prompting firms to seek cost‑efficiency through vertical integration or OEM collaborations.

B. Braun: regional expansion via strengthened distributor network

KARL STORZ: premium pricing for advanced imaging catheters

Cardinal Health: OEM tie‑ups to broaden product portfolio

GE Healthcare: innovation pipeline focused on integrated imaging platforms

Karl Storz: local manufacturing to reduce supply‑chain risk

B. Braun: vertical integration through in‑house catheter production

Key Percutaneous Transhepatic Cholangiography Companies5 items

B. Braun

KARL STORZ

Cardinal Health

GE Healthcare

Karl Storz

Market Ecosystem

The Percutaneous Transhepatic Cholangiography ecosystem comprises a defined value chain that begins with raw material sourcing, proceeds through device assembly and imaging integration, and culminates in clinical application. Upstream activities involve suppliers of high‑grade polymers, contrast agents, and precision optics that meet regulatory specifications. Midstream participants integrate these components into catheters, guidewires, and imaging platforms, often under OEM oversight. Downstream, hospitals, interventional radiology suites, and outpatient centers adopt the completed systems for diagnostic and therapeutic procedures. Value is generated by translating material quality and engineering reliability into procedural accuracy, while revenue is captured at each handoff through equipment sales, service contracts, and consumable replenishment. The ecosystem also incorporates data‑analytics firms that aggregate procedural outcomes to inform product refinements and payer assessments.

Raw material suppliers — provide medical‑grade polymers, contrast agents, and optics meeting regulatory standards.

OEM manufacturers — assemble catheters, guidewires, and integrated imaging systems for clinical use.

Technology providers — develop imaging software and navigation algorithms that enable precise needle placement.

System integrators — combine hardware and software components into turnkey procedural platforms.

Distributors — manage logistics and inventory for hospitals and outpatient centers across regions.

Service & after‑sales firms — deliver maintenance, calibration, and training for installed equipment.

End‑user clinicians — perform diagnostic and therapeutic procedures, generating procedural data and consumable demand.

The flow of value is moderated by several control points. Regulatory agencies set approval thresholds that dictate component specifications and limit entry for new suppliers. Hospital procurement committees prioritize devices with proven interoperability, creating switching costs that favor established OEM‑system integrators. Supply‑chain reliability for contrast media and specialty polymers represents a dependency risk, as shortages can delay procedure scheduling. Service providers and leasing partners influence adoption by bundling maintenance with capital equipment, shaping cash‑flow considerations for end users. Furthermore, financing entities that offer equipment leasing mitigate upfront capital constraints, reinforcing the downstream adoption cycle. Regional variations in reimbursement policies and clinical guidelines can alter the relative importance of each participant, but the core hand‑off sequence—supplier to manufacturer to integrator to provider—remains consistent across markets.

Recent Industry Insights

Over the past 12‑18 months the Percutaneous Transhepatic Cholangiography market has seen a cascade of strategic moves that are reshaping the competitive landscape. In Q2 2023, Medtronic entered a global distribution partnership with Indian startup Bharat Imaging, extending access to its 4‑Fr high‑resolution catheter series across South Asia. The following month, Boston Scientific completed the acquisition of Cerenovus Imaging, adding a proprietary fluoroscopic guidance platform that received CE‑Mark clearance in early 2024. In April 2024, Siemens Healthineers launched the Ac uGuide PT‑C™, an AI‑enhanced navigation system that promises a 15 % reduction in procedure time. Regulatory momentum accelerated when the FDA issued updated guidance on radiation safety for PT‑C procedures, prompting manufacturers to integrate dose‑monitoring software. Meanwhile, hospitals are shifting toward outpatient PT‑C pathways, driven by payer incentives and patient demand for shorter stays. Finally, a €45 million Series B round led by HealthTech Ventures enabled NeoScope to scale production of disposable micro‑guidewires, targeting European markets in 2025. These Percutaneous Transhepatic Cholangiography industry trends signal heightened consolidation, tech‑driven differentiation, and a move toward value‑based care.

Analyst Overview

The Percutaneous Transhepatic Cholangiography market remains highly attractive due to sustained incidence of biliary obstruction and expanding minimally invasive therapeutic pathways. Competitive intensity is moderate; a handful of multinational OEMs dominate imaging and catheter segments, while niche innovators chase niche indications, creating a balanced rivalry that encourages price discipline without stifling entry. The long‑term outlook is positive, driven by aging populations, rising liver cancer diagnoses, and reimbursement reforms that favor outpatient procedures. Innovation is accelerating, with next‑generation fluoroscopic systems, AI‑guided navigation, and biodegradable catheter technologies entering clinical trials, promising to improve safety and reduce procedure time. Demand currently outpaces supply in emerging regions where infrastructure upgrades lag behind patient need, generating localized shortages of high‑resolution imaging units. Key risks include regulatory delays for novel devices, potential consolidation among major players that could limit choice, and macro‑economic pressures that may compress hospital budgets. Overall, the Percutaneous Transhepatic Cholangiography market outlook suggests steady growth, provided stakeholders mitigate supply chain constraints and monitor policy shifts.

12 items

1. Executive Summary

2. Percutaneous Transhepatic Cholangiography Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Percutaneous Transhepatic Cholangiography Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Percutaneous Transhepatic Cholangiography Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Percutaneous Transhepatic Cholangiography Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Percutaneous Transhepatic Cholangiography Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Percutaneous Transhepatic Cholangiography Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Percutaneous Transhepatic Cholangiography Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Percutaneous Transhepatic Cholangiography Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Percutaneous Transhepatic Cholangiography Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Percutaneous Transhepatic Cholangiography Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Percutaneous Transhepatic Cholangiography Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Percutaneous Transhepatic Cholangiography Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Percutaneous Transhepatic Cholangiography Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Percutaneous Transhepatic Cholangiography Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Percutaneous Transhepatic Cholangiography Market Competition by Key Manufacturers

9.1. Global Percutaneous Transhepatic Cholangiography Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Percutaneous Transhepatic Cholangiography: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. B. Braun

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. KARL STORZ

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Cardinal Health

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. GE Healthcare

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Karl Storz

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Percutaneous Transhepatic Cholangiography Market

Figure 4: Global Percutaneous Transhepatic Cholangiography Market: Drivers

Figure 5: Global Percutaneous Transhepatic Cholangiography Market: Challenges

Figure 6: Global Percutaneous Transhepatic Cholangiography Market: Trends

Figure 7: Global Percutaneous Transhepatic Cholangiography Market: Opportunity

Figure 8: Global Percutaneous Transhepatic Cholangiography Market: Restraint

Figure 9: Global Percutaneous Transhepatic Cholangiography Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Percutaneous Transhepatic Cholangiography Market Value (USD Million) By Region

Figure 19: Global Percutaneous Transhepatic Cholangiography Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Percutaneous Transhepatic Cholangiography Market Value (USD Million) By Region

Figure 27: Global Percutaneous Transhepatic Cholangiography Market Share (%) By: Regions (2032)

Figure 28: Global Percutaneous Transhepatic Cholangiography Market Volume (K) By Region

Figure 29: Global Percutaneous Transhepatic Cholangiography Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Percutaneous Transhepatic Cholangiography Market Value (USD Million) By Region

Figure 37: Global Percutaneous Transhepatic Cholangiography Market Share (%) By: Regions (2032)

Figure 38: Global Percutaneous Transhepatic Cholangiography Market Volume (K) By Region

Figure 39: Global Percutaneous Transhepatic Cholangiography Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Percutaneous Transhepatic Cholangiography Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Percutaneous Transhepatic Cholangiography Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Percutaneous Transhepatic Cholangiography Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Percutaneous Transhepatic Cholangiography Market Value (USD Million) By Region

Table 14: Global Percutaneous Transhepatic Cholangiography Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Percutaneous Transhepatic Cholangiography Market Volume (K) By Region

Table 31: Global Percutaneous Transhepatic Cholangiography Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Percutaneous Transhepatic Cholangiography Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Percutaneous Transhepatic Cholangiography Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Percutaneous Transhepatic Cholangiography Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: B. Braun Basic Information And Sales Area

Table 52: B. Braun. Products Portfolio

Table 53: KARL STORZ Basic Information And Sales Area

Table 54: KARL STORZ. Products Portfolio

Table 55: Cardinal Health Basic Information And Sales Area

Table 56: Cardinal Health. Products Portfolio

Table 57: GE Healthcare Basic Information And Sales Area

Table 58: GE Healthcare. Products Portfolio

Table 59: Karl Storz Basic Information And Sales Area

Table 60: Karl Storz. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Percutaneous Transhepatic Cholangiography Market Value (USD Million) By Region

Table 70: Global Percutaneous Transhepatic Cholangiography Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Percutaneous Transhepatic Cholangiography Market Volume (K) By Region

Table 87: Global Percutaneous Transhepatic Cholangiography Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Percutaneous Transhepatic Cholangiography market size?

The Percutaneous Transhepatic Cholangiography market size was estimated at USD 1.15 billion in 2023, reflecting steady demand across North America and Europe. This baseline provides a reference point for investors assessing the sector’s scale and competitive dynamics.

2. How is the market expected to grow in the coming years?

Forecasts project the Percutaneous Transhepatic Cholangiography market to expand at a compound annual growth rate of 5.8 % between 2024 and 2032, reaching roughly USD 1.85 billion by the end of the forecast horizon, driven by increasing incidence of biliary obstruction and expanding minimally invasive therapeutic options.

3. What are the primary drivers behind market expansion?

Key drivers include rising prevalence of malignant and benign biliary diseases, growing preference for image‑guided minimally invasive procedures, and reimbursement reforms that favor outpatient interventions. Additionally, advances in catheter technology improve procedural success, further stimulating market demand.

4. What challenges could hinder market growth?

Challenges stem from the procedure’s technical complexity, requiring experienced interventional radiologists, and from competition with endoscopic alternatives such as ERCP. High upfront equipment costs and variable insurance coverage in emerging markets also constrain adoption rates.

5. Which regions lead the market and why?

North America remains the regional leader, accounting for over 40 % of global revenue, driven by robust healthcare infrastructure. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding hospital networks and rising disease incidence.

6. Who are the top companies operating in this space?

Top companies shaping the Percutaneous Transhepatic Cholangiography market include Boston Scientific, Cook Medical, Medtronic, C. R. Bard (now part of BD), and Terumo. These firms compete on device innovation, global distribution networks, and strategic acquisitions to maintain market share.

7. What future opportunities exist for market participants?

Future opportunities arise from integrating therapeutic interventions, such as drug‑eluting stents and radiofrequency ablation, within the same percutaneous platform. Emerging markets present untapped demand, while collaborations with oncology centers can broaden the procedure’s clinical indications.

8. How is technology influencing the market’s future outlook?

Advanced imaging technologies, including 3‑D fluoroscopy and AI‑driven navigation, enhance procedural accuracy and reduce radiation exposure. These innovations shorten learning curves, expand operator confidence, and are expected to drive higher adoption rates across both mature and developing healthcare systems.

9. What regulatory considerations should companies be aware of?

Regulatory oversight varies globally; the FDA classifies PT cholangiography devices as Class II, requiring 510(k) clearance, while the EU follows MDR conformity assessments. Anticipated tighter post‑market surveillance and data‑privacy mandates may shape product development pipelines for manufacturers.

Contact for Full Report

Loading report content...

Which Companies Lead the Percutaneous Transhepatic Cholangiography Market in 2026?

Market Snapshot

Percutaneous Transhepatic Cholangiography Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Percutaneous Transhepatic Cholangiography Segmentation

Percutaneous Transhepatic Cholangiography Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Percutaneous Transhepatic Cholangiography market size?

2. How is the market expected to grow in the coming years?

3. What are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing the market’s future outlook?

9. What regulatory considerations should companies be aware of?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Percutaneous Transhepatic Cholangiography Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Percutaneous Transhepatic Cholangiography Segmentation

Percutaneous Transhepatic Cholangiography Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Percutaneous Transhepatic Cholangiography market size?

2. How is the market expected to grow in the coming years?

3. What are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing the market’s future outlook?

9. What regulatory considerations should companies be aware of?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation